- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 17, 2013 P2, N=60, Active, not recruiting, Recruiting --> Active, not recruiting
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Combination therapy: PHOENIX: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 3, 2013 P3, N=800, Recruiting, Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial termination, Combination therapy: VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2013 P2, N=36, Terminated, Completed --> Active, not recruiting Active, not recruiting --> Terminated
- |||||||||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, HEOR, Surgery: Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery (clinicaltrials.gov) - Sep 1, 2013 P2, N=40, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Combination therapy, Metastases: A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies (clinicaltrials.gov) - Aug 28, 2013 P1/2, N=26, Active, not recruiting, Not yet recruiting --> Recruiting N=19 --> 26
- |||||||||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment change: Study for Treatment of Cancer in Children With Ataxia-telangiectasia (clinicaltrials.gov) - Aug 25, 2013 P=N/A, N=6, Completed, Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. N=30 --> 6
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, Enrollment closed, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 25, 2013 P2, N=100, Active, not recruiting, N=30 --> 6 Recruiting --> Active, not recruiting
|